Form 8-K Blueprint Medicines Corp For: Aug 01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Blueprint Medicines (BPMC) PT Raised to $155 at Stifel
August 1, 2024 12:14 PM EDTStifel analyst Bradley Canino raised the price target on Blueprint Medicines (NASDAQ: BPMC) to $155.00 (from $150.00) while maintaining a Buy rating.
The analyst comments "A 13% Ayvakit beat and 11% increase to the FY24 Ayvakit guidance midpoint is fundamentally positive, but for today at least... More



